PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))))) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (rCDI). Fast Track designation is a process designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.
Reported Earlier, Treasure Global Integrates Chatbot Feature Into ZCITY App, Powered By Its AI Data Analysis Engine And ChatGPT
- Chatbot Will Provide ZCITY Users With Chat And Reward Functionality And Merchants With Expanded Ability To Capture Data On User Behavior -
NEW YORK and KUALA LUMPUR, Malaysia, May 10, 2023 (GLOBE NEWSWIRE) -- Treasure
